Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Coliseum Capital Adds To Its Stake In BioScrip Inc (BIOS)

Page 1 of 10

Coliseum Capital, managed by Christopher Shackelton and Adam Gray, has recently disclosed an increase in its holding of BioScrip Inc (NASDAQ:BIOS). According to an amended filing with the Securities and Exchange Commission, the fund has acquired 4.2 million shares of common stock at a price of $2 per share as part of a public offering undertaken by BioScrip. As a result, the fund now controls approximately 23.2 million shares, which include 5.62 million shares of common stock and shares that could be obtained upon the conversion of preferred stock and warrants. The position would amount to roughly 17.6% of the company’s common stock.

A provider of infusion solutions, BioScrip Inc (NASDAQ:BIOS) has been in a steady uptrend since the start of the year, advancing by approximately 62% to yesterday’s closing price of $2.78 per share. On June 16, the company announced the pricing of the underwritten offering of 40 million shares of common stock at $2 per share, granting the underwriters the possibility to acquired an additional 5.2 million shares within the first 30 days after the offering. BioScrip expects to raise between $73.4 million and $83.2 million, depending on how the underwriters exercise their options. The company has also recently announced the acquisition of HS Infusion Holdings for $85 million, as part of its strategic development plan.

cell, stem, research, cold, liquid, nitrogen, medical, test, experiment, clothing, protective, artificial, white, temperature, laboratory, freeze, cryopreservation, samples,

Elena Pavlovich/Shutterstock.com

Hedge fund sentiment towards BioScrip Inc (NASDAQ:BIOS) was unchanged during the first quarter: 13 elite hedge funds had this stock in their portfolio at the end of March, having together amassed 38% of the company’s outstanding stock. Philip Hempleman‘s Ardsley Partners held the largest position in BioScrip among the funds followed by Insider Monkey, having indicated ownership of 6.69 million shares in its latest 13F filing. Stephen Dubois‘ Camber Capital Management held 6.18 million shares of BioScrip at the end of March, up by 17% during the quarter.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Coliseum Capital Management 0 23,182,758 0 23,182,758 23,182,758 17.6%
Coliseum Capital 8. 17,841,112 0 17,841,112 17,841,112 14.0%
Coliseum Capital Partners 0 14,553,786 0 14,553,786 14,553,786 11.6%
Coliseum Capital Partners II 0 3,287,326 0 3,287,326 3,287,326 2.8%
Adam Gray 0 23,182,758 0 23,182,758 23,182,758 17.6%
Christopher Shackelton 0 23,182,758 0 23,182,758 23,182,758 17.6%
Christopher Shackelton And Adam Gray
Christopher Shackelton And Adam Gray
Coliseum Capital

Page 1 of 10 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE
13D/A

Under the Securities Exchange Act of 1934*

(Amendment No. 3)

 

 

BioScrip,
Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

09069N108

(CUSIP Number)

Christopher Shackelton/Adam Gray

Metro Center

1 Station
Place, 7th Floor South

Stamford, CT 06902

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

June 22, 2016

(Date
of Event Which Requires Filing of this Statement)

 

 

If the filing person has
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of sections 240.13d-1(e), 240.13d-1(f) or 140.13d-1(g), check the following box.  ¨

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities
Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Bioscrip Inc. (NASDAQ:BIOS)
Trade (NASDAQ:BIOS) Now!
Page 1 of 10

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!